#TITLE_ALTERNATIVE#

• Main Author: SUMANTRI NIM : 20714317, SURYA
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/31152

Glibenclamide is a class of sulfonylureas used orally as a type 2 antidiabetic drug, <br /> <br /> categorized as a class II BCS drug because it has low solubility and bioavailability. One <br /> <br /> way to increase the dissolution rate is made in the form of nanoparticles, with <br /> <br /> Nanostructured Lipid Carrier as a delivery system. The purpose of this research is to <br /> <br /> develop Glibenclamide NLC delivery system. Formulated by screening for the selection of <br /> <br /> solid lipids (glyceryl monosterate, cetyl alcohol, stearyl alcohol and stearic acid) liquid <br /> <br /> lipids (oleic acid, virgin coconut oil, isopropyl myristate, and olive oil), varying the <br /> <br /> combination of solid lipids and liquid lipids as well as surfactants. The Glibenclamide NLC <br /> <br /> was prepared by high-speed homogenization and ultrasonication method, to an optimized <br /> <br /> Glibenclamide NLC formula, consisting of 2% glyceryl monostearate as solid lipid, 2% <br /> <br /> oleic acid as liquid lipid, 4% Polysorbate 80 as surfactant. Characterization is the <br /> <br /> measurement of particle diameter and polydispersity index, Efficiency Entrapment, <br /> <br /> Differential Scanning Microscopy, FTIR, test in simulation of gastrointestinal condition, <br /> <br /> morphological characterization with Transmission electron microscopy (TEM). NLC-GL <br /> <br /> has a particle size of 140.30 ± 1.03 nm, polydispersity index of 0.289 ± 0.068, an adsorption <br /> <br /> efficiency of 73.63 ± 0.33%. From this study it is concluded that NLC-GL has the potential <br /> <br /> to increase the solubility of the active substance, and by itself increases the bioavailability <br /> <br /> of the drug. <br />